[go: up one dir, main page]

WO2001062247A1 - Topical compositions containing thiazolium compounds and methods of using same - Google Patents

Topical compositions containing thiazolium compounds and methods of using same Download PDF

Info

Publication number
WO2001062247A1
WO2001062247A1 PCT/US2001/004304 US0104304W WO0162247A1 WO 2001062247 A1 WO2001062247 A1 WO 2001062247A1 US 0104304 W US0104304 W US 0104304W WO 0162247 A1 WO0162247 A1 WO 0162247A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
group
composition
agents
thiazolium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/004304
Other languages
French (fr)
Inventor
John A. Duffy
Dmitri S. Ptchelintsev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avon Products Inc
Original Assignee
Avon Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Products Inc filed Critical Avon Products Inc
Priority to AU2001239754A priority Critical patent/AU2001239754A1/en
Publication of WO2001062247A1 publication Critical patent/WO2001062247A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Definitions

  • the present invention relates to cosmetic and dermatological compositions. More particularly, the present invention relates to cosmetic and dermatological compositions containing thiazolium compounds.
  • Telangiectasia is a condition characterized by the dilation of one or more superficial arterioles in the human body, such that the effected arterioles become visible through the skin. In some cases, telangiectasia is symptomatic of a more serious disorder. However, telangiectasia occurs in approximately 15% of the population as a purely cosmetic problem. Telangiectasia is aesthetically objectionable and often becomes an increasingly common occurrence as an affected person ages. The objectionable nature of telangiectasia is evidenced by the common name for the disorder, i.e., "spider veins.”
  • Spider veins are readily recognizable because of the characteristic shape and angry, red color of the dilated arterioles. In addition, spider veins typically blanch if pressure is applied to the nearby skin.
  • spider veins involve invasive procedures that are intended to disrupt or destroy the arteriole.
  • hypertonic saline or octadocanol may be injected into a larger artery adjacent to the affected arterioles, which scleroses the larger artery and effective "dries up" the spider veins.
  • invasive techniques are clearly undesirable because they require delicate operations that must be performed under the supervision of a physician.
  • Alternative techniques use laser light focused on the affected arterioles.
  • pigmented creams can be used to mask the spider veins.
  • compositions have been introduced to treat spider veins.
  • U.S. Patent No. 5,268,176 discloses the use of inositol phosphoric acid and its derivative in the treatment of spider veins.
  • Topical compositions are intended to treat the affected arterioles and have several advantages, such as being non-invasive, simple, and readily available. However, topical compositions are often less than totally effective.
  • thiazolium, oxazolium, and imidozolium compounds may be used to topically treat telangiectasia or spider veins. It is believed that thiazolium, oxazolium, and imidozolium compounds act to restore the elasticity, and the healthy size and shape, of the affected arterioles.
  • a topical composition having thiazolium, oxazolium, or imidozolium compounds for skin care, dermatological applications, and the treatment of spider veins.
  • the present invention provides a method of treating spider veins by topically applying a composition having thiazolium, oxazolium, or imidozolium compounds.
  • alkyl means a straight, branched, or cyclic hydrocarbon chain, saturated or unsaturated, and unsubstituted or substituted.
  • Aryl means a moiety having an unsubstituted or substituted aromatic ring.
  • Cyclic means a moiety having an unsubstituted or substituted non-aromatic ring.
  • Anion and anionic are interchangeable and refer to any ion or compound having a negative charge.
  • compositions and methods have been developed that are believed to treat superficial arterioles affected by telangiectasia.
  • the active compounds described herein may be used to topically treat spider veins. It is believed that the active compounds restore the elasticity, and the healthy size and shape, of the affected arterioles.
  • compositions of the present invention have one or more active compounds described by the following general structure: wherein: Z is selected from the group consisting of sulfur, oxygen, and nitrogen;
  • R-i, R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thienyl, pyrrolyl, phenyl group, cyclic (saturated or unsaturated), and hydroxyalkyl groups.
  • Ri through R may represent one or more ring structures, either independently or in combination; and
  • X is an anion or anionic compound.
  • a composition according to the present invention may contain one or more of the above described active compounds in any amount up to about 90% of the total weight of the composition (wt.%), preferably up to about 50 wt.%, and, more preferably, up to about 20 wt.% in a physiologically acceptable vehicle.
  • the active compounds used in the compositions of the present invention may be prepared according to any method.
  • thiazolium compounds for use in the present invention may be prepared according to the procedures described in U.S. Patent No. 5,656,261 , which is incorporated herein by reference.
  • the active compounds are topically applied in a carrier.
  • a carrier is a formulation within which a particular active compound, such as a thiazolium compound, is applied to the skin.
  • the carrier may be a physiologically acceptable carrier that does not produce significant irritation upon contact with human skin.
  • a carrier for use in the present invention can be of any form, such as a solid, a fluid, an emulsion or an aerosol. Examples of a solid carrier include patches, tapes, powders, and other dry solid carrier obvious to those skilled in the art. Examples of a fluid carrier include creams, lotions, gels, and any other fluid carrier obvious to those skilled in the art.
  • compositions of the present invention may also contain one or more additional compounds.
  • a composition according to the present invention may contain one or more emollients (preferably in an amount up to about 30 wt.%), one or more emulsifiers (preferably in an amount up to about 20 wt.%), one or more preservatives (preferably in an amount up to about 5 wt.%), one or more alcohols (preferably in an amount up to about 95 wt.%), one or more fragrances (preferably in an amount up to about 5 wt.%)), one or more thickening agents (preferably in an amount up to about 10 wt.%), one or more humectants (preferably in an amount up to about 25 wt.%), one or more colorants (preferably in an amount up to about 1 wt.%>), one or more silicones (preferably in an amount up to about 50 wt.%), one or more exfoliating agents (preferably in an amount up to about 70 w
  • other compounds that may be incorporated into the composition include: one or more hormones (preferably in an amount up to about 5 wt.%)), one or more antibacterial agents (preferably in an amount up to about 20 wt.%)), one or more analgesics (preferably in an amount up to about 50 wt.%), one or more lipophilic compounds (preferably in an amount up to about 90 wt.%), one or more antihistamine agents (preferably in an amount up to about 20 wt.%), one or more insect repellants (preferably in an amount up to about 90 wt.%), one or more skin cooling compounds (preferably in an amount up to about 90 wt.%), one or more lubricants (preferably in an amount up to about 90 wt.%), one or more anti-fungal agents (preferably in an amount up to about 50 wt.%), one or more skin-whitening agents (preferably in an amount up to about 50 wt.%), and mixtures thereof.
  • compositions according to the present invention are examples of compositions according to the present invention.
  • Salicylic acid 1.50 Ammonium hydroxide to pH 4.0
  • a composition according to the present invention may be applied topically in any amount and according to any schedule.
  • Use of the composition is limited only by the particular circumstances of use, which may include treatment of, for example, skin pigmentation, age spots, wrinkles, lack of elasticity of the skin, poor skin texture, poor skin tone, and poor skin clarity.
  • the particular circumstances of use may also include one or more of the aesthetic goals, such as, reducing dermatological aging (particularly dermatological aging due to hormonal aging), decreasing skin fragility, preventing and reversing loss of collagen, preventing skin atrophy, promoting/accelerating cell turnover, improving skin firmness/plumpness, improving skin texture, decreasing fine lines and wrinkles, improving skin tone, enhancing skin thickness, decreasing pore size, minimizing skin discoloration, restoring skin luster, minimizing signs of fatigue, reducing acne, and improving skin clarity.
  • the aesthetic goals such as, reducing dermatological aging (particularly dermatological aging due to hormonal aging), decreasing skin fragility, preventing and reversing loss of collagen, preventing skin atrophy, promoting/accelerating cell turnover, improving skin firmness/plumpness, improving skin texture, decreasing fine lines and wrinkles, improving skin tone, enhancing skin thickness, decreasing pore size, minimizing skin discoloration, restoring skin luster, minimizing signs of fatigue, reducing acne, and improving skin clarity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

It has been surprisingly discovered that thiazolium compounds may be used to topically treat telangiectasia or spider veins. It is believed that the thiazolium compounds act to restore the elasticity, and the healthy size and shape, of the affected arterioles. Accordingly, there is provided a topical composition having thiazolium compounds for skin care, dermatological applications, and the treatment of spider veins. In addition, this invention provides a method of treating spider veins by topically applying a composition having thiazolium compounds.

Description

TOPICAL COMPOSITIONS CONTAINING THIAZOLIUM COMPOUNDS AND METHODS OF USING SAME
Background of the Invention 1. Field of the Invention
The present invention relates to cosmetic and dermatological compositions. More particularly, the present invention relates to cosmetic and dermatological compositions containing thiazolium compounds.
2. Description of the Prior Art
Telangiectasia is a condition characterized by the dilation of one or more superficial arterioles in the human body, such that the effected arterioles become visible through the skin. In some cases, telangiectasia is symptomatic of a more serious disorder. However, telangiectasia occurs in approximately 15% of the population as a purely cosmetic problem. Telangiectasia is aesthetically objectionable and often becomes an increasingly common occurrence as an affected person ages. The objectionable nature of telangiectasia is evidenced by the common name for the disorder, i.e., "spider veins."
Spider veins are readily recognizable because of the characteristic shape and angry, red color of the dilated arterioles. In addition, spider veins typically blanch if pressure is applied to the nearby skin.
There are several techniques presently used to treat spider veins.
First, several techniques for the treatment of spider veins involve invasive procedures that are intended to disrupt or destroy the arteriole. For example, hypertonic saline or octadocanol may be injected into a larger artery adjacent to the affected arterioles, which scleroses the larger artery and effective "dries up" the spider veins. However, such invasive techniques are clearly undesirable because they require delicate operations that must be performed under the supervision of a physician. Alternative techniques use laser light focused on the affected arterioles. Furthermore, pigmented creams can be used to mask the spider veins.
More recently, topically applied compositions have been introduced to treat spider veins. For example, U.S. Patent No. 5,268,176 discloses the use of inositol phosphoric acid and its derivative in the treatment of spider veins. Topical compositions are intended to treat the affected arterioles and have several advantages, such as being non-invasive, simple, and readily available. However, topical compositions are often less than totally effective.
In light of the foregoing, there is an on-going need for a topically applied compositions useful for treating dermatological conditions and, especially, spider veins.
Summary of the Invention
It is an object of the present invention to provide a topical or dermatological composition.
It is also an object of the present invention to provide a topical or dermatological composition useful for the treatment of telangiectasia or spider veins.
It is a further object of the present invention to provide such a composition useful for the treatment of telangiectasia or spider veins, which contains thiazolium, oxazolim, or imidozolium compounds.
It is yet another object of the present invention to provide a method of treating telangiectasia or spider veins.
It has been surprisingly discovered that thiazolium, oxazolium, and imidozolium compounds may be used to topically treat telangiectasia or spider veins. It is believed that thiazolium, oxazolium, and imidozolium compounds act to restore the elasticity, and the healthy size and shape, of the affected arterioles.
Accordingly, there is provided a topical composition having thiazolium, oxazolium, or imidozolium compounds for skin care, dermatological applications, and the treatment of spider veins. In addition, the present invention provides a method of treating spider veins by topically applying a composition having thiazolium, oxazolium, or imidozolium compounds.
Detailed Description of the Invention
As used herein, "alkyl" means a straight, branched, or cyclic hydrocarbon chain, saturated or unsaturated, and unsubstituted or substituted. "Aryl" means a moiety having an unsubstituted or substituted aromatic ring. "Cyclic" means a moiety having an unsubstituted or substituted non-aromatic ring. "Anion" and "anionic" are interchangeable and refer to any ion or compound having a negative charge.
In accordance with the present invention, compositions and methods have been developed that are believed to treat superficial arterioles affected by telangiectasia. Specifically, it has been surprisingly discovered that the active compounds described herein may be used to topically treat spider veins. It is believed that the active compounds restore the elasticity, and the healthy size and shape, of the affected arterioles.
The topical compositions of the present invention have one or more active compounds described by the following general structure:
Figure imgf000004_0001
wherein: Z is selected from the group consisting of sulfur, oxygen, and nitrogen;
R-i, R2, R3, and R4 are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thienyl, pyrrolyl, phenyl group, cyclic (saturated or unsaturated), and hydroxyalkyl groups. Ri through R may represent one or more ring structures, either independently or in combination; and
X is an anion or anionic compound.
When Z is oxygen, sulfur, or nitrogen, the above formula yields oxazolium, thiazolium, or imidozolium compounds, respectively.
A composition according to the present invention may contain one or more of the above described active compounds in any amount up to about 90% of the total weight of the composition (wt.%), preferably up to about 50 wt.%, and, more preferably, up to about 20 wt.% in a physiologically acceptable vehicle.
The active compounds used in the compositions of the present invention may be prepared according to any method. For example, thiazolium compounds for use in the present invention may be prepared according to the procedures described in U.S. Patent No. 5,656,261 , which is incorporated herein by reference.
According to the present invention, the active compounds are topically applied in a carrier. As used herein, a carrier is a formulation within which a particular active compound, such as a thiazolium compound, is applied to the skin. The carrier may be a physiologically acceptable carrier that does not produce significant irritation upon contact with human skin. A carrier for use in the present invention can be of any form, such as a solid, a fluid, an emulsion or an aerosol. Examples of a solid carrier include patches, tapes, powders, and other dry solid carrier obvious to those skilled in the art. Examples of a fluid carrier include creams, lotions, gels, and any other fluid carrier obvious to those skilled in the art.
In addition to above described active compounds, the compositions of the present invention may also contain one or more additional compounds. For example and without limitation, a composition according to the present invention may contain one or more emollients (preferably in an amount up to about 30 wt.%), one or more emulsifiers (preferably in an amount up to about 20 wt.%), one or more preservatives (preferably in an amount up to about 5 wt.%), one or more alcohols (preferably in an amount up to about 95 wt.%), one or more fragrances (preferably in an amount up to about 5 wt.%)), one or more thickening agents (preferably in an amount up to about 10 wt.%), one or more humectants (preferably in an amount up to about 25 wt.%), one or more colorants (preferably in an amount up to about 1 wt.%>), one or more silicones (preferably in an amount up to about 50 wt.%), one or more exfoliating agents (preferably in an amount up to about 70 wt.%)), one or more keratolytic agents (preferably in an amount up to about 50 wt.%)), one or more retinoids (preferably in an amount up to about 10 wt.%)), one or more sunscreens, such as avobenzene, octyl salicylate, octyl methoxycinnamate, and octocrylene (preferably in an amount up to about 30 wt.%), one or more skin penetration enhancers (preferably in an amount up to about 25 wt.%), one or more anti- inflammatory agents (preferably in an amount up to about 50 wt.%), one or more vitamins (preferably in an amount up to about 50 wt.%), one or more thrombolytic agents (preferably in an amount up to about 50 wt.%), one or more anticlotting agents (preferably in an amount up to about 30 wt.%), one or more capillary protectants (preferably in an amount up to about 70 wt.%), and one or more antioxidants (preferably in an amount up to about 80 wt.%).
Furthermore, other compounds that may be incorporated into the composition include: one or more hormones (preferably in an amount up to about 5 wt.%)), one or more antibacterial agents (preferably in an amount up to about 20 wt.%)), one or more analgesics (preferably in an amount up to about 50 wt.%), one or more lipophilic compounds (preferably in an amount up to about 90 wt.%), one or more antihistamine agents (preferably in an amount up to about 20 wt.%), one or more insect repellants (preferably in an amount up to about 90 wt.%), one or more skin cooling compounds (preferably in an amount up to about 90 wt.%), one or more lubricants (preferably in an amount up to about 90 wt.%), one or more anti-fungal agents (preferably in an amount up to about 50 wt.%), one or more skin-whitening agents (preferably in an amount up to about 50 wt.%), and mixtures thereof.
The following are examples of compositions according to the present invention.
Exampl e 1: Oil-ln-Water Emulsion Composition
Inqredient Wt.%)
3-(2-methyl-2-oxoethyl)-thiazolium chloride 1.00
Glyceryl stearate 8.00
Cetearyl alcohol 1.50
Cetearyl Octanoate 1.50
Octylpalmitate 4.00
Butylene Glycol 5.00
Glycerine 4.00
Methyl Paraben 0.40
Fragrance 0.01
Water qs
Example 2: Cream Composition
Inqredient wt.%
Cetyl alcohol 2.00 Glyceryl monostearate 2.50
3-propargyl-4-methyl-thiazolium bromide 0.50
White Petrolatum 5.00
3,4-dimethyl-5-(2-hydroxyethyl)-thiazolium iodide 5.00 Octyl Palmitate 8.00
Steareth-2 1.00
Peg-40 Stearate 2.00 Triethanolamine to pH=6.00 Water qs
Example 3: Lotion Composition
Inqredient wt.%
Xanthan Gum 0.25 Hydroxyethyl cellulose 0.35
3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride 2.00
Propylene glycol 5.00
Tocopherol 0.10
Caprylic/Capric triglyceride 9.00 Steareth 2 1.50
Lactic acid 2.00 Ammonium hydroxide to pH 3.8
Water qs
Example 4: Toner
Ingredient wt.%
Ethyl alcohol 40.00
2-(2-phenyl-2-oxoethyl)-4-methylthiaxolium bromide 10.00
Glycerine 5.00 Disodium EDTA 0.25
Lactic acid 1.00
Salicylic acid 1.50 Ammonium hydroxide to pH 4.0
Water qs
Example 5: Ointment
Inqredient wt.%>
Petrolatum 68.99 Shae butter 10.00
Lipophilic rosemary extract 0.01
Apigenin 1.00
3-(2-methoxy-2-oxoethyl) benzothiazolium chloride 20.00
Example 6: Anhydrous Tonic
Inqredient Wt.%)
Silicone oil 3300..0000
Propylene glycol 22..0000
Phenethyl isothiocyanate 00..0011
3-(2-phenyl-2-oxoethyl)thiazolium chloride 00..55
Fragrance 00..1155
Colorant 00..0011
Anhydrous ethanol qqss
Example 7: Silicone Emulsion
Inqredient wt.%
Cyclomethicone/Dimethicone copolyol 10.00
Cyclomethicone pentamer 15.00
Sodium Chloride 0.50
Glycerine 5.00
Preservative 0.15
Decylisothiocyanate 1.00
3-(2-phenyl-2-oxoethyl)-4-methylthiazolium chloride 5.00 water qs
In use, a composition according to the present invention may be applied topically in any amount and according to any schedule. Use of the composition is limited only by the particular circumstances of use, which may include treatment of, for example, skin pigmentation, age spots, wrinkles, lack of elasticity of the skin, poor skin texture, poor skin tone, and poor skin clarity. The particular circumstances of use may also include one or more of the aesthetic goals, such as, reducing dermatological aging (particularly dermatological aging due to hormonal aging), decreasing skin fragility, preventing and reversing loss of collagen, preventing skin atrophy, promoting/accelerating cell turnover, improving skin firmness/plumpness, improving skin texture, decreasing fine lines and wrinkles, improving skin tone, enhancing skin thickness, decreasing pore size, minimizing skin discoloration, restoring skin luster, minimizing signs of fatigue, reducing acne, and improving skin clarity.
The present invention having been described with particular reference to the preferred forms thereof, it will be obvious that various changes and modifications may be made herein without departing from the spirit and scope of the invention as defined in the appended claims.

Claims

Wherefore we claim:
1. A method for the treatment of telangiectasia comprising the step of topically applying to said telangiectasia a composition including one or more active compounds described by the following general structure:
Figure imgf000011_0001
wherein:
Z is selected from the group consisting of sulfur, oxygen, and nitrogen;
R-i, R2, R3, and R4 are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thienyl, pyrrolyl, phenyl group, cyclic, and hydroxyalkyl groups. R1 through R may represent one or more ring structures, either independently or in combination; and
X is anionic.
2. A method for the treatment of the skin comprising the step of topically applying to said skin a composition including one or more active compounds described by the following general structure:
Figure imgf000011_0002
wherein:
Z is selected from the group consisting of sulfur, oxygen, and nitrogen;
R-i. R2, R3, and R are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thienyl, pyrrolyl, phenyl group, cyclic, and hydroxyalkyl groups. R-i through R4 may represent one or more ring structures, either independently or in combination; and X is anionic.
3. The method of claim 2, wherein said treatment is for one or more of the conditions selected from the group consisting of: skin pigmentation, age spots, wrinkles, lack of elasticity of the skin, poor skin texture, poor skin tone, poor skin clarity.
4. A method for improving the aesthetic appearance of the skin comprising the step of topically applying to said skin a composition including one or more active compounds described by the following general structure:
Figure imgf000012_0001
wherein:
Z is selected from the group consisting of sulfur, oxygen, and nitrogen;
Ri, R2, R3, and R are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thienyl, pyrrolyl, phenyl group, cyclic, and hydroxyalkyl groups. R1 through R may represent one or more ring structures, either independently or in combination; and X is anionic.
5. The method of claim 4, wherein the improvement in aesthetic appearance includes at least one of the following: a. Reducing dermatological aging, particularly dermatological aging due to hormonal aging; b. Decreasing skin fragility; c. Preventing and reversing loss of collagen; d. Preventing skin atrophy; e. Promoting/accelerating cell turnover; f. Improving skin firmness/plumpness; g- Improving skin texture; h. Decreasing fine lines and wrinkles; i. Improving skin tone; j. Enhancing skin thickness; k. Decreasing pore size;
1. Minimizing skin discoloration; m. Restoring skin luster; n. Minimizing signs of fatigue; o. Reducing acne; and
P- Improving skin clarity.
6. A composition for topical application to telangiectasia, said composition comprising a physiologically acceptable carrier and one or more active compounds described by the following general structure:
Figure imgf000013_0001
wherein:
Z is selected from the group consisting of sulfur, oxygen, and nitrogen;
Rι. R2, R3, and R are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thienyl, pyrrolyl, phenyl group, cyclic, and hydroxyalkyl groups. R-i through R may represent one or more ring structures, either independently or in combination; and X is anionic.
7. The composition of claim 6, wherein said one or more active compounds are selected from the group consisting of: 3-(2-methyl-2- oxoethyl)-thiazolium chloride, 3-propargyl-4-methyl-thiazolium bromide, 3,4-dimethyl-5-(2-hydroxyethyl)-thiazolium iodide, 3-ethyl-5-(2- hydroxyethyl)-4-methylthiazolium chloride, 2-(2-phenyl-2-oxoethyl)-4- methylthiaxolium bromide, 3-(2-methoxy-2-oxoethyl) benzothiazolium chloride, 3-(2-phenyl-2-oxoethyl)thiazo!ium chloride, 3-(2-phenyl-2- oxoethyl)-4-methylthiazolium chloride, and mixtures thereof.
8. The composition of claim 6, wherein said physiologically acceptable carrier may be applied to skin without irritation and is selected from the group consisting of comprises a solid, a fluid, an emulsion, an aerosol, and mixtures thereof.
9. The composition of claim 8, wherein said physiologically acceptable carrier is selected from the group consisting of: patches, tapes, powders, a dry solid, creams, lotions, gels, and combinations thereof.
10. The composition of claim 6, further comprising one or more additional compounds selected from the group consisting of: emollients, emulsifiers, preservatives, alcohols, fragrances, thickening agents, humectants, colorants, silicones, exfoliating agents, keratolytic agents, retinoids, sunscreens, skin penetration enhancers, anti-inflammatory agents other than thiazolium compounds, vitamins, thrombolytic agents, anticlotting agents, capillary protectants, antioxidants, hormones, antibacterial agents, analgesics, lipophilic compounds, antihistamine agents, insect repellants, skin cooling compounds, lubricants, anti-fungals, and mixtures thereof.
PCT/US2001/004304 2000-02-25 2001-02-12 Topical compositions containing thiazolium compounds and methods of using same Ceased WO2001062247A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001239754A AU2001239754A1 (en) 2000-02-25 2001-02-12 Topical compositions containing thiazolium compounds and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18492500P 2000-02-25 2000-02-25
US60/184,925 2000-02-25

Publications (1)

Publication Number Publication Date
WO2001062247A1 true WO2001062247A1 (en) 2001-08-30

Family

ID=22678879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004304 Ceased WO2001062247A1 (en) 2000-02-25 2001-02-12 Topical compositions containing thiazolium compounds and methods of using same

Country Status (2)

Country Link
AU (1) AU2001239754A1 (en)
WO (1) WO2001062247A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1543824A3 (en) * 2003-12-17 2005-09-14 Avon Products, Inc. Thiazole derivatives to counter advanced glycation
US7109202B2 (en) 2000-11-21 2006-09-19 Novartis Ag Aminothaizoles and their use as adenosine receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268176A (en) * 1991-07-22 1993-12-07 Avon Products, Inc. Method and compositions for the non-invasive treatment of telangiectasia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268176A (en) * 1991-07-22 1993-12-07 Avon Products, Inc. Method and compositions for the non-invasive treatment of telangiectasia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109202B2 (en) 2000-11-21 2006-09-19 Novartis Ag Aminothaizoles and their use as adenosine receptor antagonists
EP1543824A3 (en) * 2003-12-17 2005-09-14 Avon Products, Inc. Thiazole derivatives to counter advanced glycation

Also Published As

Publication number Publication date
AU2001239754A1 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
US5885595A (en) Cosmetic composition with a retinol fatty acid ester
US20040102358A1 (en) Composition for treating skin conditions
AU2020273346B2 (en) Methods and compositions for topical delivery for skin care
US6248763B1 (en) Composition for treating skin conditions
JP2002363058A (en) Use of a composition comprising at least one chelating agent to increase the tolerance of sensitive or intolerant skin
BRPI0116293B1 (en) topical composition to prevent, ameliorate or treat skin hyperpigmentation
US5891451A (en) Skin treatment with salicylic acid esters
CA2411058C (en) Skin treatment using a new retinoid
KR100564386B1 (en) 4-hydroxy-5-methoxy-4- [2-methyl-3- (3-methyl-2-butenyl) -2-oxalanyl] -1-oxaspiro [2,5] octane-6- Pharmaceutical composition for treating seborrhea containing ions
EP1273285A2 (en) Use of 5'-desoxy-5'-methylthioadenosine in cosmetic skincare compositions
US20030095991A1 (en) Treatment for skin
WO1997030690A1 (en) Skin treatment with salicylic acid esters
EP1635779B1 (en) Cosmetic peeling method using urea
US5741497A (en) Skin treatment with salicylic acid esters
JPH0899819A (en) Anti-fungus pharmaceutical preparation for making-up and dermatology
EP1192940A1 (en) Compositions and methods for promoting clear skin using an alkanolamine
KR20030005258A (en) Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials
WO2001062247A1 (en) Topical compositions containing thiazolium compounds and methods of using same
CN101374493A (en) Compositions beneficial to skin and methods of use thereof
CN1121850C (en) Use of unfermented honey as decolouring agent
EP1310241B1 (en) Skin treatment using a retinoid
WO2003053327A2 (en) Compositions containing a retinoid and malt extract
JPH11246389A (en) Bleaching composition
KR20000018488A (en) Pharmaceuticals for skin
AU2006201889A1 (en) Treatment for skin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP